Apriori Bio

Apriori Bio is a biotechnology company focused on developing variant-resilient vaccines and antibody drugs to protect against rapidly evolving viruses. Founded in 2020, the company utilizes a unique AI-driven platform called Octavia™ to analyze the complete spectrum of existing and potential viral variants. Octavia™ identifies the most concerning variants and designs vaccines that can effectively combat current and future threats, potentially eliminating the need to constantly chase new variants.

Apriori Bio is a Flagship Pioneering company, backed by a team of experts in the fields of immunology, virology, vaccine development, and artificial intelligence. The company has received substantial funding from organizations like CEPI, demonstrating its commitment to global health security. Their innovative approach aims to preempt future outbreaks and create a world where humanity is protected against viral threats.

Apriori Bio is a biotechnology company dedicated to safeguarding humanity from the threat of rapidly evolving viruses. Their mission is to create a world where future outbreaks are preventable by developing variant-resilient vaccines and antibody drugs. They achieve this by leveraging their unique AI-powered platform, Octavia, which surveys the entire landscape of existing and potential viral variants to predict and design vaccines against the most dangerous threats. Apriori aims to provide proactive protection against viral outbreaks, empowering humanity to stay ahead of evolving threats.

Apriori Bio fosters a culture of innovation and collaboration, driven by a shared mission to protect humanity from viral threats. The company attracts truth-seekers who are meticulous and rigorous in their scientific approach, while also being agile, bold, and passionate about their work. Apriori values a diverse and inclusive team, encouraging open communication and a collaborative spirit to achieve their goals.